Table 2.
Previous clinical trials for ovarian clear cell carcinoma.
| Trials | Patients | N | Arms/Treatments | ORR | Median PFS/ 2-Year Disease-Free Survival Rate *** |
Median OS/ 2-Year Survival Rate *** |
|---|---|---|---|---|---|---|
| JGOG3014 [22] | Stage I-IV First-line |
99 | TC* × 6 CPT-P × 6 |
40 25 |
NA NA |
NA NA |
| JGOG3017 [23] | Stage I-IV First-line |
667 | TC** × 6 CPT-P × 6 |
46.7 29.4 |
77.6% *** 73.0% *** |
87.4% *** 85.5% *** |
| GOG268 [24] | StageIII/IV First-line |
45 (Japan) 45 (US/Korea) |
TC** + Temsirolimus 25 mg/body × 6 →Temsirolimus 25 mg/body |
71 (Japan) 54 (US/Korea) |
12 (Japan) 11 (US/Korea) |
26 (Japan) 23 (US/Korea) |
| GOG254 [25] | Recurrent | 35 | Sunitinib 50 mg/day | 6.7 | 2.7 | 12.8 |
| NRG-GY001 [26] | Recurrent | 13 | Cabozantinib 60 mg/day | 0 | 3.6 | 8.1 |
Abbreviations: TC*, Paclitaxel 180 mg/m2, Carboplatin AUC6 on day1 every 3weeks; TC**, Paclitaxel 175 mg/m2, Carboplatin AUC6 on day1 every 3 weeks; CPT-P, Irinotecan 60 mg/m2 on days1,8,15, Cisplatin 60 mg/m2 on day1 every 4 weeks; ORR, Objective response rate; PFS, Progression-free survival; OS, Overall survival. *** p < 0.005.